NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets protein-based biosurgery and passive immunotherapy products, will announce financial results for the fourth quarter and full year ended December 31, 2007 before the opening of the U.S. financial markets on Thursday, March 6, 2008. An accompanying conference call to discuss the results will be held the same day at 11:00 am ET; 8:00 a.m. PT.
